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INTRODU CTION

Much of what we know about the human immune system has been
discovered by studying patients with defective immunity and comparing
their defects with the systems of normal patients.

One of the more fas¬

cinating of these defective immune systems is seen in the Wiskott-Aldrich
syndrome (WAS), a sex-linked recessive and usually fatal disorder char¬
acterized by eczema, abnormal platelets, recurrent infections, and broad
defects in humoral and cell-mediated immunity.

In an attempt to better

understand this disorder numerous attempts have been made to elucidate
the cell line responsible for the immune defects.

At one time or another,

however, every hematogenous cell line except the erythrocyte has been
suggested as a possible contributor.

Except for the fact that the disease

can be cured by complete bone-marrow stem cell replacement, the meta¬
bolic and cellular basis for the disorder remain unknown.
In an attempt to clarify much of the immunologic work done on WAS
patients in the past, this thesis presents an angle of attack completely
different from any yet applied to this disorder.

A study of the X-chromo-

some inactivation patterns in the carriers of this disorder was undertaken
in an attempt to locate possible cellular defects responsible for the ex¬
pression of the syndrome.

Results suggesting the location of this cellular

defect as well as a possible method for detecting the carrier state will be
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presented.

The possible application of this technique to the study of

other sex-linked recessive immunologic diseases will be discussed as
well.
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BRIEF HISTORICAL SKETCH

A syndrome of thrombocytopenia, eczema, and repeated infections
was first described in a single patient by Wiskott^ in 1937.

The second

description of this syndrome appeared seventeen years later in 19 54 when
Aldrich e_t al/^) noted the sex-linked recessive nature of this clinical triad
in a large family.

Huntley and Dees^) observed the presence of eosino-

philia and milk allergy and were the first to suggest that splenectomy was
followed by increased susceptibility to infections.
Defects in immunologic function were demonstrated by many.

West

e_t al^) first described decreased serum IgM and elevated IgA levels.
Krivit and Good^ showed that these WAS children had deficient antibody
production in response to certain bacterial antigens.
ated immunity was described by Cooper et al/*^.

Deficient cell-medi¬

Absence of isohemagglut¬

inins was reported by Krivit et al/^ and Pearson et al^) who also suggested
that thrombocytopenia was due to decreased platelet survival time.
Cooper et al/^) suggested that this disorder was progressive and
that the immune response of these patients deteriorated with age.

Blaese

et al^^felt that the defects in both humoral and cellular immunity could
be explained by a defect in antigen processing or recognition.

Cooper^11)

postulated a defect in a B-lymphocyte subline whereas bone marrow trans¬
plantation work by Park man e_t al ^

suggested a T-lymphocyte defect.

-4-

Abnormalities in other cell lines have been shown as well, although to
a lesser degree.
The clinical course of this disorder has been well described by
Steihm and Fulginiti^).

Those patients with the more severe forms of

the disorder succumb to hemorrhage or severe infections within the first
few years of life whereas those with the milder forms have been reported
to survive at least into their mid-twenties.

The initial manifestations of

the syndrome are thrombocytopenia, which is often present at birth, and
eczema, which invariably develops within the first four to six months of
life.

As the WAS child ages the bleeding problems often subside whereas

the eczema frequently becomes severe and may at times be difficult to
distinguish from superficial infection of the skin.

Recurrent bacterial

and viral infections make their life quite miserable.

Pneumococci,staphylo¬

cocci, cytomegalovirus, herpes simplex, and Pneumocystis carinii are
some of the more common infecting organisms.

Hematologic and immuno¬

logic support of these children often prolongs life.

Many however often

go on to develop lymphoreticular tumors.
As will be shown in greater detail below, the defects in platelets
and humoral and cell-mediated immunity have been well characterized by
many different individuals.

These defects and their pathophysiology

however remain poorly understood and the cellular or metabolic basis for
the disease remains unknown.
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GENETICS AND EPIDEMIOLOGY

Wiskott-Aldrich syndrome is fortunately a rare disorder with an
estimated prevalence of less than one case per million individuals in the
United States.

There is no known ethnic or socioeconomic predispo¬

sition for this syndrome.

It has been reported in the medical literature of

Japan, Italy, France, Poland, Germany, the Soviet Union, Hungary,
Czechoslovakia, and the United States and probably exists elsewhere.
It is however a disorder requiring a sophisticated medical care system for
diagnosis and will probably not be reported at all in countries with a
high infant mortality rate.
Aldrich et al/^) were the first to demonstrate the genetics of this
syndrome by studying the transmission of the trait in a large family who
had kept detailed family records for the proceeding four generations.
Because of its sex-linked recessive nature the syndrome is passed from
unaffected mother to affected son.

Boys born to a carrier mother thus have

a 50% chance of acquiring the disorder while daughters have a 50% chance
of becoming carriers themselves.
Although this disorder is usually fatal early in life, a few males
have survived to a reproductive age'^#
reports of them having fathered children.

^.

There are however no

WAS can therefore be considered

an X-linked lethal disorder wherein a certain number of WAS genes are
removed from the gene pool each generation.

To maintain the presence of

this disorder in a population these removed genes must therefore be replaced
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by new mutations.

-

Haldane^) calculated that with respect to an X-linked

lethal gene one third of all affected males per generation would represent
new mutations, assuming identical mutation rates in maternal and paternal
germ cells and that the population was in equilibrium for this gene.

These

newly mutated males should therefore have normal homozygous mothers.
This hypothesis was tested by Francke et al^^^ in families with LeschNyhan disease, a well studied X-linked recessive and lethal disorder in
which the carrier state can be readily detected^ *21).

-phey found that the

incidence of new mutations in heterozygous mothers was close to that pre¬
dicted but that the number of normal homozygous mothers with affected
was significantly lower than predicted.

sons

They concluded from this that

Haldane's theory might not be accurate, at least for Lesch-Nyhan disease.
Because of the inability to detect the carrier state in WAS we cannot
test Haldane's hypothesis.
this theory.

However, two points should be inferred from

The first is that adequate genetic counseling is very difficult

without a method for detection of the carrier state.

Currently we can tell

the daughter who has two brothers with WAS, with fair certainty, that she
has a 50% chance of carrying the disease.

But what does one tell the

daughter who has only one brother with WAS and an otherwise completely
negative family history?

Remember that a certain percent of affected males

will be spontaneous mutations, but that a certain number of carrier mothers
will be spontaneous mutations as well.

In one case the daughter has a 0%

chance of being a carrier and in the other a 50% chance.

The need for a

method to detect the carrier state is therefore quite obvious.

Even if this
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need were met however, many of the possible carriers still desire children.
Carriers of course have a 25% chance of giving birth to an affected male
with each pregnancy.

A method for detecting WAS males in utero would

thus be helpful for these families as well.
The second point to infer from Haldane's theory is that even if pre¬
natal diagnosis and a method for detecting the carrier state were available,
a certain number of carrier females and WAS males representing spontaneous
mutations would still be born in previously unaffected families.

This num¬

ber is unknown but may be as high as 33% of all affected males currently
being born if Haldane's hypothesis is correct.

WAS will thus always be

with us and an understanding of the disease and methods to effectively
treat it still necessary.
In practice, the women of families with one or more WAS patient
are divided into several groups:

obligate carriers, probable carriers,
e

possible carriers, and probable normals (see Table 1 for definitions).
This division will in the future allow us to study the carrier state with
greater precision for it is from this group that we feel the answers to
WAS will be forthcoming

8
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PATHO PHYSIOLOGY

The abnormalities of thrombocytopenia, eczema, and the multiple
humoral and cellular immune defects seen in WAS

are difficult to link

together under a single pathogenetic mechanism.

It must be remembered

also that this is an inherited disorder and every cell in the body carries
the WAS gene, although only a few seem to express it.

Exactly which

cell lines express the defect and which are responsible for the multiple
defects of the disorder is still under debate.
The thrombocytopenia in affected males has been the best studied
aspect of WAS.

Its etiology is felt not to be secondary to the immune

problems since it is almost always seen immediately at birth whereas the
immune difficulties usually do not appear until several months later^^.
Severe hemorrhage is often reported at circumcision and melena or bloody
diarrhea is often present within the first month of life^' 17,22).
thrombin and partial thromboplastin times are normal.

pro_

Platelet counts,

often immediately after birth, are in the range of 15,000 to 40,000 per
mm^ (normals for newborns are 125,000 to 250,000 per mm^ and increase
only slightly with age).
One of the first explanations for this thrombocytopenia was possible
splenic sequestration since many of the affected children had slight to
moderate splenomegaly on physical examination^ ' ^.

Many of the

patients with chronic thrombocytopenia underwent splenectomy for this
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reason.

-

Most of these patients did indeed show a transient rise in plate¬

let count after splenectomy but their counts invariably returned to their
pre-surgery levels within a few weeks^4)#

jj- was noted however that

these splenectomized patients had a very high incidence of severe and
often fatal pneumococcal infections within one to two months after sur¬
gery (3/24).

Because of this problem and the failure to correct the thrombo¬

cytopenia, splenectomy is now avoided unless other pressing medical
needs dictate.
Another explanation for the thrombocytopenia had to be considered
and the question of possible decreased platelet production was addressed.
A review of bone marrow aspirate and biopsy results on these patients
shows that most had
(o

cytesvo'

17 ?2 24-27)
'

'

normal to slightly increased numbers of megakaryoalthough one group reported absent megakaryocytes

in two out of their three patients(28).

Megakaryocyte morphology in these

stained biopsies was usually reported as normal.

However, Pearson et al^

noted little active platelet formation despite the presence of nuclear hyper¬
segmentation, karyorrhexis, and degenerate nuclei which are reportedly
seen only when the megakaryocyte is actively shedding platelets.

Baldini

also felt the megakaryocytes in his patients were abnormal, expressing
features of immaturity such as vacuolization and spongy cytoplasm^?).
Although no platelet production studies were done on these children it was
generally felt that ineffective thrombopoesis was only partially responsible
for their thrombocytopenia.
The major cause of the thrombocytopenia was felt by many (though
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without good evidence) to be of an autoimmune nature similar perhaps to
that responsible for idiopathic thrombocytopenic purpura (ITP)^9)#

How¬

ever, Pearson et al^ showed that normal donor platelets infused into WAS
boys had a normal survival time.

Others, using ^^r-labelled platelets

from WAS children, showed markedly decreased platelet survival times
when infused into both WAS males and normal volunteers ^2 • ^ .

This

data implied that the thrombocytopenia was due to increased destruction
secondary to some intrinsic platelet defect rather than merely decreased
platelet production.

The other implication of these experiments was that

platelet transfusions could be given with confidence to WAS males when
/o

31)

faced with surgery or other hemorrhagic eventsv '
Studies on the morphology of the platelets from WAS males have been
most interesting.

It has been shown repeatedly by light microscopy, elec¬

tron microscopy, and protein content assays that these platelets are on
the average only 65% the size of normal platelets(22 ' 25-27).

jn addition,

this abnormal platelet size has been confirmed by platelet-size distribution
studies using particle-counting electronics (see figure

1)^2).

gome groups

have reported that WAS platelets contain decreased numbers of alpha-gran¬
ules, mitochondria, dense core bodies, and other internal structures despite
their smaller size^22'2^'2^.

More recently however, others have reported

normal numbers of intra-platelet organelles^6 /32).

Qr5ttum(22) reported

widespread phagocytosis of these abnormal platelets by marrow macro¬
phages and concluded that the decreased platelet survival seen in these
patients might be due to recognition and phagocytosis of the morphologically
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abnormal circulating platelets by the reticuloendothelial system.
The question of abnormal platelet physiology in WAS has been the
subject of great debate for the last ten years.

It has been shown that

platelets from many WAS males exhibit decreased nucleotide storage
pools (22) # defects in platelet adhesiveness in response to collagen^ / 27)

f

and failure to undergo the second phase of aggregation when stimulated
with epinephrine, ADP, or collagen^ • ^.

However, Hadden et al(33)

felt that these in vitro results could be explained solely by the smaller
size and lower number of platelets in the WAS patients.

Others have

reported that "if carefully concentrated" the WAS platelets displayed normal
adhesiveness and aggregation^)#
For a solution to the small size and decreased number of platelets in
the WAS males many investigators turned to the obligate carriers of this
disorder since they have normal platelet size and numbers'1

.

Although

not considered at the time, this approach does not make sound theoretical
sense for reasons that will be discussed at length later.

Surprisingly how¬

ever, many of the aggregation defects seen in the abnormal platelets of
affected males have also been reported in their mothers despite the fact
that the mothers were normal in every other respect and expressed none of
the signs of the disorder seen in their affected sons ^ '30,34).
aggregation defects in the mothers appear to be variable however.
It has been recently proposed by Shapiro et al^4) that the defect
of aggregation may be caused by the genetic absence of some physiological
stimulator of the Krebs cycle.

They felt that the platelets were still able
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to undergo secondary aggregation but were merely more sensitive to inhibit¬
ion of this aggregation than normal platelets.

In addition, they have pro¬

posed a method for detecting the carrier state based on this principle.

The

details of these experiments will be discussed and criticized at length
later in this thesis.
In summary, it is generally agreed that the bleeding problems in WAS
males are secondary to decreased circulating platelet mass which itself
results from the production of abnormally small platelets combined with
shortened platelet survival time.

Shortened lifespan has been attributed

to intrinsic platelet defects or peripheral phagocytosis or both.

The rate

of platelet production is probably decreased but has not been proven.
basis for the production of these abnormal platelets is unknown.

The

The physio¬

logical platelet defects have not been seen by all investigators and their
existence and possible significance remain

under debate.

Aside from the thrombocytopenia, the remaining abnormalities in
WAS can be categorized as defects in cellular and humoral immunity.

These

defects however are difficult to tie together under one unifying hypothesis
although many authors have tried.
Recurrent bacterial infections are the most serious problem in this
disorder, accounting for 55% of all deaths^),

WAS children are most

vulnerable to infection with staphylococci, pneumococci, and a variety
of gram-negative organisms despite the fact that they have a normal com¬
plement system and normal numbers of polymorphonuclear leucocytes with
normal granulocyte function^

^.

The only defect observed in this

13

-

-

system was by S pi tier et_ a_l ^ ^ who noted that granulocytes from four of
nine WAS boys failed to adhere to nylon fiber columns.
and nitroblue tetrazolium tests were normal, however.

Bacterial killing
This defect has

not been reported elsewhere and its significance is unknown.
Total serum immunoglobulins are normal as are IgG and IgD fractions.
Serum IgE levels have been noted to be elevated in some patients ^6).

one

of the classic findings in WAS however has been a persistently low IgM with
slightly elevated IgA^

although these levels are usually within two

standard deviations of the normal mean.

Another classical finding is the

virtual absence of isohemagglutinins —naturally occurring IgM-class anti¬
bodies to the common blood group antigens-- in these patients (5 / 7 / 8).
Isohemagglutinin titers in blood group O WAS patients are in the range of
1:2 or less compared to titers of >1:16 seen in normal individuals.

Immuno¬

globulin synthesis in response to protein antigens is often normal in
affected boys whereas they almost always exhibit very poor antibody for¬
mation against polysaccharide antigens.

Cooper et al^ felt that the low

IgM seen in many of these patients could be explained by their inability
to make antibody against the polysaccharide antigens since much of the
antipolysaccharide antibody in normal patients is of the IgM class.

The

slightly elevated IgA levels seen in some of these patients have not been
explained.
Lymph node biopsies, at least early in life, usually show an abund¬
ance of germinal centers and plasma cells ^ ^ .

The thymus is present

and undergoes normal morphological development^*).

The total lymphocyte
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count in these children is normal as are the total numbers of circulating
B and T-lymphocytes ^ 1 '^5) #

Despite the normal development of these

cellular components however, most WAS patients are completely anergic.
They show absolutely no delayed hypersensitivity response when skintested with ubiquitous antigens or with dinitrochlorobenzene (DNCB) sen¬
sitization^

/10 #23).

skin homograft rejection, another cell-mediated

immune response, is often impaired in these children as well.
These results all imply a severely impaired cell-mediated immune
response and may explain the increased susceptibility to viral and fungal
infections often seen in these

children^),

since cell-mediated mechanisms

are also responsible for the cytotoxic T-lymphocytes postulated as playing
a role in immune surveillance, a failure of these mechanisms may also
explain the frequent development of lymphoreticular malignancies seen in
these children.
Despite absence of cell-mediated immunity by in vivo skin testing,
many authors have noted a normal or only slightly decreased response of
lymphocytes to in vitro phytohemagglutinin (PHA) or mixed-lymphocyte
37,38)#

stimulation^/

These observations coupled with the evidence that

the machinery for humoral and cell-mediated responses was present led
Cooper et al^ to suggest that the defect in WAS was in the afferent limb
of immunity.

They felt that the ability to process the antigen, the transfer

of the immune message to the effector cell, or the ability of the effector
cell to recognize the immune message was somehow defective.
Several authors have tried to explain the broad defects in immunity
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as resulting from immunologic attrition as the affected child ages.
et

al^/9)

Cooper

suggested that the variable results of immune function studies

were dependent on the age at which the patient was tested.

Younger child¬

ren, for example, have normal lymph nodes and respond fairly well to a
number of protein antigens. In contrast, older patients often display
marked degeneration of parafollicular (T-lymphocyte) and germinal center
(B-lymphocyte) areas at lymph node biopsy and often show poor response
to protein antigens.

Steihm and McIntosh^) and others (?) showed that

the classic immunoglobulin picture of low IgM and elevated IgA evolves
with time over the first year or so of life.

Cooper et al(9) then suggested

that the attrition may be related to an inability to process polysaccharide
antigens and that the efferent limb of immunity atrophied secondary to
lack of stimulation.
Blaese et al^®) also felt that this defect might lie in the failure to
process antigens and they postulated a possible defect of monocyte/macro¬
phages .

These cells are known to play a very important role in presenting

antigens to certain lymphocyte subpopulations in the afferent limb of immun¬
ity (39) and their failure to do this might certainly produce defects in both
humoral and cellular immunity.

Kuramoto e_t al.(25) suggested that the

alpha-granules in the macrophages as well as the platelets might be metabolically defective but this has not been proven.

Since normal macrophages

play a large role in phagocytizing opsonized antigens the ability of WAS
macrophages to do this was investigated.

Spitler et al^5) examined the

IgG receptors on monocyte/macrophages from affected children and found
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slightly diminished receptors in some but not all of their WAS patients.
The presence of this finding did not correlate with the severity of the
disease and its significance is unknown.

Others have reported normal

monocyte IgG receptors in their WAS patientsIn addition, Blaese
<2t

al(40)

incubated normal macrophages with lymphocytes from WAS patients

and were unable to show improved lymphocyte response to in vitro antigen
stimulation.

They concluded that the basic defect in WAS did not involve

monocyte/macrophage function.
The eczema seen in all of these patients is the most difficult mani¬
festation of the disorder to explain.

This partly stems from the fact that

we still know very little about the pathophysiology of eczema even in
normal individuals.

Many feel that the eczema seen in normal patients

is a type of cell-mediated immune reaction but this explanation is doubt¬
ful in WAS patients since they appear to have absent or severely diminished
cell-mediated immunity.
antibodies

Many of these affected boys have skin-sensitizing

to common allergens and a few have developed food allergies

responses which are IgE-mediated in normal patients.

WAS males often

have elevated IgE levels and eosinophilia but it is unknown whether these
are a cause of their immediate hypersensitivity symptoms or merely a second¬
ary result of other immune deficiencies.

The eczema in WAS may well be

mediated by the elevated IgE or eosinophilia or may be secondary to the
major humoral and cell-mediated defects.

However, no one has yet to pro¬

pose a pathophysiological mechanism.
Perhaps more light can be thrown on the confusing picture of these
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multiple immune defects by considering the results of treatment of this
disorder.

Several different modalities have been tried, but can be classi¬

fied under two basic categories:

immune or hematologic support, and

actual attempts to correct the cause of the immune defects.

Support in

the form of immune globulin injections or plasma, erythrocyte, and plate¬
let transfusions have prolonged life and ameliorated some acute infectious
phases but on the whole have not improved the miserable immune functions
in these patients
Better results have been shown with attempts to correct the unknown
cause of the immune defects.

The two most promising methods in the last

few years have been bone marrow transplants and treatment with transfer
factor.

Transfer factor treatment, since it is simple and has few risks,

might show great potential for therapy of WAS.

Transfer factor is

a small dialysable molecule prepared from sensitized leucocytes of normal
individuals which is able to transfer specific immunity to deficient patients
by an unknown mechanism.

It has shown great potential in the treatment

of chronic mucocutaneous candidiasis
Transfer factor therapy in WAS has been reported in some cases to
clear or improve the eczema, reduce infections, and decrease the frequency
of bleeding episodes, although not correcting the thrombocytopenia^
These changes however are inconsistently seen and the effect of transfer
factor is difficult to judge because the course of WAS is so highly variable.
Most recently, a controlled double blind clinical trial of transfer factor
in the treatment of WAS has shown no in vivo or in vitro improvement of
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cellular reactivity and no improvement in clinical condition of four WAS
patients (43).
The best results in treatment of this disease have been obtained with
complete autologous bone marrow transplantation which, in two cases, has
restored these children to completely normal immune and hematologic func¬
tion^).

it must be realized however that bone marrow transplantation is

suitable for very few WAS patients.

As with transplantation of other organs,

the major difficulty is in finding an HLA-compatible donor.

Other major

problems include the dangers of potent immunosuppressive therapy, infection,
and graft-versus-host disease.

The remarkable results obtained in these

two cases however can shed some light on the possible location of defects
in WAS.
The first bit of information is that WAS can be totally cured by com¬
plete stem cell replacement.
marrow transplant failed.

In one of the cases however, the first bone

The only marrow cell line that "took" in that

first graft was the T-lymphocyte line.
of the child's eczema.

This resulted in complete clearing

His anti-A isohemagglutinin titer, which had been

1:4 prior to transplantation, rose to 1:64 and his concentration of antibodies
to polyribose phosphate (a polysaccharide antigen) rose as well.

Over the

next nine months his T-lymphocyte karyotype gradually returned from female
(donor) to male (host).

Despite the return of his own T-lymphocy tes, the

child's eczema did not recur.

At the end of nine months the patient's hemo-

poetic and lymphoid cell lines were entirely of recipient karyotype with no
evidence of persistence of any donor cells.

Anti-A and B isohemagglutinin
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titers had dropped to 1:2 and the anti-polyribose phosphate antibody con¬
centration had dropped as well.
This T-lymphocyte replacement and gradual return along with the
marked improvement in immune response and its gradual return to the pre¬
transplantation levels is compelling evidence that the defect in the immune
system of these WAS children lies within the T-lymphocyte.

The possi¬

bility that another cell line such as the monocyte "took" along with the
T-lymphocytes, was responsible for the immune changes, and then returned
to host karyotype along with the lymphocytes cannot be ruled out, of course.
The authors make no mention of having looked at any hematogenous cell
populations other than lymphocytes, granulocytes, and platelets.
The inherited genetic nature of the disease implies that every nuc¬
leated cell in the body of affected males carries the gene.

The marrow

transplant results however imply that the WAS defect is expressed only
in cells of bone marrow origin.

Exactly which of the stem cell progeny

actually express the WAS gene remains unknown.

We do know that plate¬

lets and, by inference, megakaryocytes are affected.

Some authors have

suggested that the immune problems are a result of defective monocyte/macrophages(9#10) or a B-lymphocyte subline^H although the B-lymphocyte
theory was disproven just prior to publication.

The marrow transplantation

work implies that the defect may be solely in the T-lymphocyte.

One group

has even reported a defect, perhaps incidental, in the granulocyte.

The

only hematogenous cell line that no one has implicated is the erythroid
series
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The primary defect in WAS might be expressed in a single hemato¬
genous cell line which, by its defective interaction with other normal cell
lines, may then lead to a chain reaction culminating in the observed broad
immune defects of the syndrome.

On the other hand, all of the cell lines

or perhaps even just a subgroup may be expressing the gene.

Our under¬

standing of the complex interactions of these different lines in normal
individuals is still so rudimentary that an answer to the problem in WAS
still eludes us.
Attempts to locate the expression of the WAS defect to particular
cell lines are thus a valid approach to understanding not only this disorder
but the network of cellular interactions in the normal system as well.
approach may also point us in the direction of specific immune therapy
for WAS children in the future.

This
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THE CARRIER STATE

One possible way to locate the particular cell lines responsible for
WAS might be to examine the expression of this disorder in the carrier
mothers since these women in theory should be heterozygous mosaics for
the trait.

In the early work on this disorder many attempts were made to

identify the carrier state but it was noted time and time again that the
obligate carrier mothers were completely normal.

They had no problems

with infections, no eczema, and no thrombocytopenia.

It was shown

that the concentrations of their serum immunoglobulins were normal(^8)/
as were their isohemagglutinin titers.

They had normal lymphocyte num¬

bers and function, and their cell-mediated immunity responses to delayed
hypersensitivity skin testing and in vitro PHA stimulation were normal as
well<35>.
Hematocrits and platelet counts in carrier mothers are normal, as
are their platelet survival times.

In addition, unlike the small platelets

seen in the affected males the platelets from obligate carriers have a
normal size distribution when compared to normals (see figure i)(27 /32).
Their platelet protein content —a rough measure of volume— is normal
and no abnormalities of platelet organelles have been seen under the
electron microscope(27).
In contrast to this boring normality however, platelet physiology
appears to be abnormal in many of these carrier mothers.

Baldini^?)

noted that although platelet adhesiveness in response to collagen was
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Classification of WAS carriers:

Definitions

1.

Obligate carriers:

Women with two or more WAS sons; or
women with one WAS son and a positive
family history for WAS.

2.

Probable carriers:

Women with only one WAS son and an
otherwise negative family history. Also
appearing in this group are daughters of
obligate carriers who have no WAS child¬
ren but with WAS appearing in the families
of their female descendants.

3.

Possible carriers:

Women who are daughters of an obligate
carrier, but who have not had any male
children, and have no WAS children in the
families of their female descendants.

4.

Probable normals:

Women with a positive family history for
WAS but who have had one or more normal
sons but no WAS sons, and in whose female
descendants' families there are no WAS boys

AFFECTED MALES
-—

FIGURE 1.

FEMALE

CARRIER

Platelet size distribution in Wiskott-Aldrich syndrome.

With the use of an Electrozone Celloscope (Particle Data Corp.# Elmhurst
Illinois), which divides the cell population into 128 windows, Murphy
et al(32) showed that three affected brothers had abnormally small plate¬
lets, whereas their mother's platelets fell within the normal range. The
standard, a polyvinyltoluene particle with a volume of 3.86 (j.^ peaks in
the window marked by the arrow. It should be noted that the curve for the
mother's platelets falls completely within the normal range and does not
display a peak or shoulder in the windows in which the smaller platelets
of her affected sons are found. This indicates that the mother does not
have a dual population of normal and abnormal sized platelets (see text
for further explanation).
This graph is a representation of the work done by Murphy et al^2):
N. Engl. J. Med. 286(10):499, 1972 and is used here as an illustration
only.
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normal in the two mothers he studied, the second phase of platelet aggrega¬
tion in response to epinephrine, ADP, and collagen were almost completely
lacking in one mother (see figure 2).

The other mother was missing only

the secondary aggregation in response to epinephrine, the responses to
ADP and collagen being normal.

As mentioned previously, these platelet

defects are seen in the affected males as well.
Baldini also noted that when platelets were incubated with latex
beads normal individuals showed a ten to twelve-fold increase in ^CC>2
production from ^C-glucose.

This response was "defective" in the WAS

mother and no reaction was seen at all in the affected sons^O).
et al(25) were able to repeat this work on a different mother.

Kuramoto

They showed

that, like her two WAS sons, she was missing the second phase of platelet
aggregation in response to epinephrine.
14

CC>2 and

14

C-lactate from

14

In addition, the production of

C-glucose by the mother's platelets when

stimulated with epinephrine was intermediate between the levels seen in
her sons and a normal control.
However, in a second mother that Baldini studied, the aggregation
defect was found only with epinephrine and could not be demonstrated in
every determination^^.

He also mentioned that another group observed

a defect of platelet aggregation with epinephrine that was clear-cut but
inconstant in three WAS mothers.
Most recently, Shapiro et al^) studied six different families con¬
taining eight obligate and two probable WAS carriers.

They found that the

secondary aggregation in response to stimulation by collagen, thrombin.
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FIGURE 2. Schematic representation of results of platelet aggregation
using epinephrine with the platelets of two affected WAS children and
their carrier mother.
The control curve was obtained with platelets from the normal sibling.
Platelets were collected in citrated blood and adjusted to 500 000 per p.1
in autologous plasma. Aggregation was studied by the use of an aggregometer recording the changes of optical density.
These results were obtained by Kuramoto et al^5) , N. Engl. J. Med.
282(9):475, 1970 and their graph is shown here to illustrate the aggre¬
gation defect reportedly found in carriers and affected males by several
different authors (see text).
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ADP, and epinephrine was completely normal.

In order to see if they could

elicit an aggregation defect they undertook an experiment to selectively
block one or the other of the two metabolic pathways that generate ATP
required for secondary aggregation.

By selectively blocking the glycolysis

pathway they were able to elicit the aggregation response only in normal
platelets.

The platelets from the WAS carriers failed to aggregate exactly

as described by Kuramoto et _al^5) ancj Baldini^).

If Shapiro et

blocked

only oxidative phosphorylation both normal and WAS carrier platelets under¬
went normal aggregation.

If both pathways were blocked simultaneously,

both groups of platelets failed to aggregate.

Because WAS carrier platelets

were sensitive to blockage of glycolysis, Shapiro et al_ concluded that
these platelets already contained an intrinsic blockage of oxidative phos¬
phorylation, and that the molecular defect in WAS was possibly the absence
of some molecular stimulator of oxidative phosphorylation or the Krebs cycle.
This is an attractive hypothesis.

However, it now appears that this

elicitable aggregation defect is often variable and can be seen, for example,
in normal men and normal pregnant women^^.

In addition, our understand¬

ing of platelet physiology responsible for secondary aggregation responses
is in its infancy.

Several authors have recently observed that certain lipo¬

philic extracts of onions^), or even a single meal containing onions^),
could completely or partially block the second phase of platelet aggregation
in normal individuals.

These results certainly cloud the validity of the

findings seen in the platelets of WAS carriers.
Let us stop for a minute and consider some of the genetic aspects
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of WAS and the carrier state.
recessive disorder.

-

It is an accepted fact that WAS is an X-linked

As in other X-linked recessive diseases, it is presumed

that males express the trait because they express only one X-chromosome,
and that heterozygous (carrier) females do not express the trait because
they have two X-chromosomes, the normal allele on one "making up" for
the defective allele on the other.

This pattern is seen in several X-linked

recessive disorders such as color blindness, Lesch-Nyhan disease, hemo¬
philias A and B, and Duchenne's muscular dystrophy

.

It is widely accepted however that all females are mosaics regarding
X-chromosome activity.

This hypothesis of mosaicism was first postulated

in 1961 by Mary Lyon^'7^ in an attempt to explain X-chromosome dosage
compensation in females.

Although called the Lyon Hypothesis for his¬

torical reasons, it is now regarded as proven fact.

It has been shown that

one of the two X-chromosomes in each cell becomes genetically inactive
at a very early stage of embryonic development.

Which of the two X-chromo¬

somes becomes inactivated is a random event, but once that inactivation
takes place that same chromosome remains inactivated in all the progeny
of that original cell.

Each female is therefore a mosaic with roughly half

of her cells expressing the paternal X-chromosome and the other half ex¬
pressing the maternal X-chromosome.

If a female is a heterozygous carrier

for a mutant allele on the X-chromosome, on the average half of the cells
in each of her tissues will be normal and the other half will express the
mutant allele.
For example, even though the carriers of hemophilia A or B manifest
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no bleeding problems, they have been shown to have anti-hemophilic factor
levels intermediate between normal levels and the absent or greatly dimin¬
ished levels of their affected sons^).

Lesch-Nyhan disease is similar

in that affected males lack the enzyme hypoxanthine phosphoribosyl trans¬
ferase (HPRT).

The HPRT levels in most tissues of the carrier mothers are

intermediate between affected males and normal patients.

In addition,

cloning studies have shown that, on the average, half the individual cells
in the carrier mothers express full HPRT activity and the other half individ¬
ually express no activity at all^O).
In these cases, the normal cells in the carrier mothers produce
enough anti-hemophilic factor or HPRT to make up for the deficient cells
and prevent the mothers from manifesting any form of the disease.

Occas¬

ionally, however, a woman heterozygous for an X-linked recessive trait
will, by the ill luck of the draw, express a greater percentage of mutant
allele than normal allele-bearing cells and thus may express a mild to
severe form of the disease depending on the percentage of cells expressing
the mutant allele.

This happens rarely but has been seen, for example,

in hemophilia and glucose-6-phosphate dehydrogenase (G6PD) deficiency
In these cases the percent of cells expressing the normal allele in each
tissue is so small that the product or effect they produce cannot completely
make up for the deficiency expressed by the majority of cells.

Under these

circumstances then, a heterozygous woman may express all or part of an
X-linked recessive disorder.
Let now return to the Wiskott-Aldrich syndrome.

If we accept the
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Lyon Hypothesis as fact, then the obligate carriers of WAS should be
mosaics for the disorder.

In other words, roughly one half of the cells in

each tissue should carry the mutant WAS allele and the other half should
carry the normal allele.

We might thus expect to see immunity and platelet

defects in the obligate carriers that are intermediate between normal
and the severe defects seen in their hemizygous affected sons.

We know

however that the mothers are completely normal except for some proposed
minor defects in platelet physiology.
One might argue that the immune defects are not seen in the mothers
because their normal cells are able to compensate in some way for the
defects expressed by the abnormal WAS cells.

For example the normal cells

might produce a stimulating factor or provide a necessary cellular function
not found in the abnormal cells.

The carrier mothers could then have a

qualitatively normal immune system despite a dual population of affected
and normal cells.
An alternative and equally feasible explanation for the normal immunity
in the carrier mothers might be that the abnormal cells expressing the WAS
gene have been selected against .

One method by which this could happen

is non-random inactivation of only the chromosome bearing the WAS allele.
However, non-random X-inactivation has been seen in humans only in
the case of those females having one normal chromosome and one structur¬
ally abnormal chromosome(49).

The X-linked genes of these individuals

are thus expressed as in a male.
A second method by which the WAS cells could be selected against
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is competition.

-

If the WAS cells in each tissue were in some way less

competitive for survival they might be replaced in time by the normal cells
simply because the normal cells were more viable.

If, as has been sug¬

gested, the cells in which the WAS gene is expressed have a defect in
energy production via oxidative phosphorylation, then this idea is entirely
plausible.
Exactly which cell lines in the carrier mother could be selected
against in this fashion

is open to conjecture.

All the cells in the affected

boys carry the WAS gene, but the defect appears to be expressed only in
cells of hematogenous origin.

We might find in the carrier mothers that

all the cells that carry the WAS gene have been replaced, but this is
doubtful.

A more likely finding might be that only the cells that express

the WAS defect are

selected against.

If this were indeed the case, and

if the WAS gene was initially expressed in the same cell line in mother and
son prior to selection, then it might be possible to determine the defective
cell line in the WAS boys by studying the selection patterns in their mothers.
Suppose for example that the WAS defect is expressed only in the
monocyte/macrophage.

If our selection theory is true then we would expect

that the defective monocyte/macrophage in the carrier mother had been
selected against at some point in development and the mother would then
have only one population of monocyte/macrophages:
the normal allele.

those expressing only

If we did indeed find this in obligate carriers then we

might infer that the monocyte/macrophage is the cell responsible for the
expression of the disorder in the affected males.

This of course rests on
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the assumption that selection occurs only against cells that express the
WAS defect, and that the defect is expressed in the same cell lines in
mother and son.
Let us now consider the case of the platelets in the carrier mothers.
If the obligate carriers are mosaics for WAS and no selection has taken
place, then these women should have two populations of megakaryocytes
in the bone marrow.

One would therefore expect to find two populations

of platelets in the peripheral blood.

The population of platelets derived

from normal megakaryocytes should have normal morphology and physiology,
and the population derived from WAS megakaryocytes might be expected
to resemble identically the abnormal platelets seen in the affected males.
One must remember however that the platelets from WAS males have
a reduced survival time, even when infused into normal persons(22).

jf

we assume that the thrombocytopenia in affected males is due solely eto
increased destruction, that their rate of platelet production is the same as
in normals, and that the two platelet populations in obligate carriers

follow

these criteria then we would expect a reduced survival time in the carrier
platelets derived from the WAS megakaryocytes.

Thus even if the carrier

had equal populations of WAS and normal megakaryocytes one would expect
that most of the platelets in the peripheral blood would be of the normal
type.

The average platelet count in affected males is around 25,000 per

mm^ whereas the average platelet count in normal adults is, say 250,000
per mm^.

jf the same processes giving rise to these counts in affected

boys and normals are going on simultaneously in the carrier mothers then
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one might expect that roughly ten percent of their platelets would be of
the abnormal type while the remaining ninety percent would be of the normal
type.
However, the experimental evidence accumulated to date does not
support the idea of two separate populations.

No one has found a popula¬

tion of abnormally sized platelets in the carrier mothers.

Perhaps the

best evidence for this is the platelet size distribution study done by
Murphy et al^^^(see figure 1).
lets existed in the carrier that

If two populations of different sized plate¬
this group studied, one would expect the

size distribution curve to exhibit two peaks; one smaller peak correspond¬
ing to the abnormal platelet pool and a much larger peak corresponding to
the normal platelet pool.

Their technique was sensitive enough that it

should have been able to detect the presence of abnormally sized platelets
in the carrier even if that pool made up only ten percent of the total platelet
count.

Their results, however, show only one peak;

that corresponding to

the pool of normal control platelets.
There are two ways to explain this result.

The first possibility is

that there is indeed a pool of abnormally small WAS platelets but it com¬
prises much less than ten percent of the total platelet count and thus
cannot be differentiated from background on our sizing machine.

The sec¬

ond possibility is that there are indeed no small platelets present.

For

practical purposes however, the first possibility can be considered a sub¬
category of the second possibility, as will be demonstrated below.
If we assume from this information that there are no small platelets
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present in the peripheral circulation of the obligate carriers then there are
three possible explanations.

Let us assume first that the carrier mother

is a mosaic for WAS and had two equal populations of megakaryocytes.
The first and least likely explanation for the apparent absence of abnormal
platelets is that they are indeed produced but are destroyed so rapidly
in the periphery that we cannot detect them.

If we could detect the presence

of the WAS allele in a cell population we would then expect to see a hetero¬
zygous megakaryocyte population but only a hemizygous normal platelet
population.
The second explanation for the absence of small platelets, still
assuming a mosaic population of megakaryocytes, is that the abnormal
megakaryocytes are now producing normal size platelets, perhaps in res¬
ponse to some unknown factor that is missing in the affected males but
is now supplied by the normal cells in the carrier mother.

If this were the
<?

case then we would expect to see a genetically heterozygous population
of platelets as well as megakaryocytes.
The third and most attractive explanation however, is that even
though the carrier mother is a mosaic for WAS, she has a non-mosaic popu¬
lation of megakaryocytes.

The megakaryocytes carrying the WAS allele

might have undergone non-random X-inactivation or they might have been
selected against and overgrown by her normal megakaryocytes.

All of her

platelets, since they were derived from normal megakaryocytes, should
thus have a normal size distribution and normal physiology.

In this case

we would expect to see a genetically hemizygous normal population of
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bo th platelets and megakaryocytes.
If this latter theory is true, how then can one explain the work on
carrier platelets which is reported to show defects in secondary aggrega¬
tion and putative defects in oxidative phosphorylation?

This work implies

that all or most of the carrier platelets are physiologically abnormal.

If

the carrier mothers are indeed mosaics and no selection has taken place
then at the very least a large number of their platelets should be completely
normal.

If, in addition to the mosaicism, selection against the WAS mega¬

karyocytes has taken place then all of their platelets should be normal and
express none of the defects reportedly seen.

Yet the physiological defects

do seem to be present, at least according to some authors.
Three possible explanations that consider both the size data and
the physiological data as well as the requirements of the Lyon Hypothesis
come to mind.

The first explanation assumes that the two mosaic popu¬

lations of megakaryocytes are present and that the normal cells exert some
unknown positive influence on the WAS megakaryocytes, enabling them to
produce normal sized platelets.

Cells carrying the WAS gene then exert

some negative influence upon the normal sized platelets causing them to
exhibit abnormal physiological responses.

Shapiro et al^4) suggested

that the platelets from WAS carriers lacked an enzyme critical to ATP gener¬
ation via the Krebs cycle and oxidative phosphorylation.

Since our mini¬

theory assumes that most of the platelets in the carriers are of genetically
normal origin they should not be lacking any necessary enzyme, but perhaps
the putative physiological defect can be explained by a soluble factor origin-
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ating from the WAS cells that inhibits one of the necessary Krebs cycle
enzymes.
The second explanation is identical to the first except that we now
make the assumption that selection against the WAS megakaryocytes has
taken place and all the platelets are now of genetically normal origin.
now no longer need the postulated positive

We

influence and can reconcile

the physiologic and anatomic data with the proposed existence of only a
single negative influence causing abnormal physiological responses in
genetically normal platelets.
The third explanation that considers the Lyon Hypothesis, the size
data, and the physiologic data is that the size data, or the physiological
data, or both could be wrong.

The size data, however, appears to be

believable, since Murphy et al^2)(see also figure 1) could readily detect
the smaller sized platelets of the WAS boys.

On the other hand, the relia¬

bility of the physiological data may be seriously questioned, as pointed
out previously.

If this data is false and the physiological defects do not

exist then the remaining observations tend to support a clonal selection
theory, at least for the megakaryocytes.
At any rate, it should be obvious that a knowledge of the interactions
of the normal and abnormal cells in the mosaic carriers of WAS

might be

of great help in answering questions about the cellular origin of the defect
in affected males as well as the question of why the heterozygote carriers
appear unaffected immunologically.

An understanding of these interactions

might also solve much of the controversy over the existence of abnormal
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platelet physiology in the carriers and perhaps point us in the direction
of a method for detecting the presence of the carrier state.
How then can we approach this problem?

The ideal method would

be to analyze each different tissue or cell line in the carrier for the pres¬
ence or absence of the WAS allele.

We are as yet unable to do this.

If,

however, we could detect the presence of a product of a different gene on
the same X-chromosome, we could then use the product of this other gene
as a "genetic marker" for the presence or absence of the WAS gene in a
single cell, a clone, a cell line, or a heterogeneous tissue.

This "genetic

marker" technique has been used frequently to study several other X-linked
recessive diseases, most notably Lesch-Nyhan disease, hemophilias A and
B, and Hunter's syndrome.

The technique has been used most extensively

to unravel the behavior of the normal X-chromosome in females and to gather
data in support of the Lyon Hypothesis.
The X-linked genetic marker most commonly used for these experi¬
ments is G6PD, which has two common isoenzyme variants that are easily
detected.
moment.

The ideal advantages of this marker will be discussed in a
If, however, we could follow the distribution of the two G6PD

isoenzymes in the cell populations of mothers who were heterozygous for
both WAS and G6PD, it could give us an excellent understanding of Lyonization and cell selection processes in these women, as well as answer
many of the other questions we have outlined previously.
exactly what we have done.

Indeed, this is
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GLUCOSE-6-PHOSPHATE DEHYDROGENASE
AS A GENETIC MARKER

Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme found in
all cells which participates in the metabolism of glucose via two major
pathways, the hexose monophosphate shunt (HMP) and the Embaen-Meyerhof
pathway of anaerobic glycolysis.

The HMP supplies the cell with NADPH,

with 5-carbon sugars required for the synthesis of nucleotides, and main¬
tains glutathione in the reduced state.

Anaerobic glycolysis is most

important in erythrocyte metabolism where it supplies ATP to power the ion
pumps and to phosphorylate membrane proteins.

It also supplies the cell

with NADH to maintain hemoglobin in the reduced form^S).
Deficiency of this enzyme was discovered as a result of studies on
the hemolytic anemia induced in some individuals by the antimalarial
drug primaquine, a strong oxidant.

The history of this study makes a fas¬

cinating story and has been covered well by Beutler^).
In the course of study of G6PD deficiency over eighty different forms
of the enzyme have been discovered, some with normal activity and some
with reduced activity.

Most of these isoenzymes are quite rare.

The most

common deficient enzyme has been classified as A“, the A referring to its
electrophoretic mobility and the (“) referring to its decreased activity in
the red blood cells (RBCs).

When the A” enzyme is first produced within

the cell its activity is very close to normal but the lifespan of the individ¬
ual enzyme molecule is considerably shortened.

Thus, reticulocytes from
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an individual who is G6PD-A" express normal enzyme activity at first, but
rapidly lose activity as the cell ages and the enzyme degrades.

These older

cells with decreased enzyme levels are then more sensitive to hemolysis
in the presence of oxidizing drugs.

However, nucleated cells from an indi¬

vidual who is G6PD-A” have normal levels and activities of this enzyme
regardless of cell age since they contain a nucleus which continues to
produce active enzyme and thus maintains a normal activity within the

( , ).

0611 50 51

The most common normal G6PD isoenzyme is classified as G6PD-B, the B
referring to its electrophoretic mobility.

The most common normal variant

is G6PD-A which, unlike the A- variant, does not degrade with time and
thus has normal activity.
on electrophoresis.

The A variants migrate faster than the B variant

The reason for this difference in electrophoretic mobil¬

ity is the presence of a single amino acid substitution;

an asparagine in

the B variant is substituted for an aspartic acid in the A variant^, 53).
The genotype for G6PD is denoted as Gdx, the (x) denoting the specific
isoenzyme type.

For example, a woman heterozygous for G6PD types A and

B would have a genotype designated by GdA/GdB.

Since the gene controlling

the G6PD isoenzyme type is located on the X-chromosome, males are hemizygous, i.e., they possess only one G6PD gene since they have only one
X-chromosome.

Since females have two X-chromosomes they possess two

G6PD genes and can be either homozygous or heterozygous for this locus.
As mentioned previously, the B isoenzyme is the most prevalent type.
The incidence of the A, A”, and other variants varies widely according to
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ethnic group.
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For example, the A and A” variants are most common in

groups of black African ancestry

/ 55).

^he gene frequencies of the most

common isoenzyme types in the United States are listed in Table 2.

As

can be seen from this table, the combined frequency of GdA/Gd^ and
Gd^/Gd® heterozygotes among American black women is 0.42.

In other

words, 42% of American black females are G6PD heterozygotes.
The G6PD enzyme system is an ideal one for us to use as a genetic
marker.

The enzyme is

the single protein product of a single gene^)#

It can be isolated as a pure product from hemizygous males, it is found
in all cells of the body, it is fairly easily identifiable by electrophoresis
on cellulose acetate or starch gels, and it has been widely used with good
success in the past.

One of the special advantages of the G6PD isoenzyme

system as a genetic marker is that neither the A, A", nor B isoenzyme is
detrimental to the cell.

In other words, a cell is at no selective advantage

or disadvantage if it expresses one of these isoenzyme types since each
type has the same activity.
In addition, much work has already been done on the distribution
of G6PD isoenzyme types in cell populations of normal individuals.

It

has been shown time and time again that tissues from a G6PD heterozygote
can be separated into two clones, each expressing only one isozyme (49).
Both Migeon and Kennedy(^6) ancf Fialkow^^ have shown that inactivation
of G6PD genes (and by inference, the whole X-chromosome) takes place
early in embryonic development, the latter author estimating that this pro¬
cess might occur as early as the 16-cell embryoblast stage.

Gartler et al^®)
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TABLE 2

I.

Polymorphous glucose-6-phosphate dehydrogenase gene frequencies
in the United States.

population group
blacks
non-blacks
Eskimos

B

G6PD isoenzyme types
other
A"
A

.70
1.00
1.00

.18

.12
sp

sp
sp

(sp = sporadic reports)

II.

Glucose-6-phosphate dehydrogenase genotype frequencies in Amer¬
ican blacks, assuming Hardy-Weinberg equilibrium.

BB
frequency

.49

combined frequency

.49

G6PD genotypes
AB
A"B
(AA, AA~, A”A“)
.252

.168

\

.42

/

.09
.09

Data for both I and II are derived from Betke et al^5); World Health Org.
Techn. Rep. Ser. #366, p 4 (1967).
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stud ied X-inactivation by simultaneously following the isoenzyme patterns
of two different enzymes widely separated on the X-chromosome.

They

found a woman who was doubly heterozygous for both HPRT deficiency and
G6PD, and then studied the recombination patterns of these four markers.
They found that single cell clones (all the cells of which should be express¬
ing the same X-chromosome) always contained the same two isoenzyme pairs.
For example, each clone contained either G6PD-B and (-f)HPRT activity,
or G6PD-A and (-)HPRT activity, but never a combination of the two.

The

authors inferred from this pattern that the entire X-chromosome within a
given cell was inactivated, and that no crossovers occurred between acti¬
vated and inactivated X-chromosomes within the cell.
Others have shown that the ratio of G6PD isoenzymes within a single
normal heterozygote appears to be remarkably constant from tissue to
tissue, and cell line to cell line.

This has been observed in erythrocytes,

granulocytes, lymphocytes, skin fibroblasts, and skeletal muscle by
Fialkow^

.

This constancy has been extended to other cell types as

well, most notably platelets(59), T-lymphocytes(60), ancj monocyte/macro¬
phages (61).

These observations have great bearing on the experiments we

have proposed, as will be discussed later.
Several authors have applied this knowledge of G6PD isoenzyme
distribution to the study of the clonal origin of various tumors and other
diseases^/63).

gy observing that certain cell groups from G6PD hetero¬

zygotes with these various diseases contained only one isoenzyme type
rather than the mixture seen in normals, the clonal origins of chronic lympho-
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cytic leukemia

-

chronic myelocytic leukemia ^1'

agnogenic myeloid

metaplasia(65), polycythemia vera^^, atherosclerotic plaques (66)# as well
as a host of solid tumors(67) have been determined.
Polymorphous G6PD is thus an excellent marker for studying the Xchromosome.

It is the most common X-linked genetic variant known, the

isoenzymes can be easily differentiated chemically, and the presence of
one isoenzyme over the other is of no selective advantage to the cell.
Most important, this enzyme has been very well studied in normal individ¬
uals, and the ratio of isoenzymes is remarkably constant from tissue to
tissue.

All of these reasons make it a very attractive marker to use in

attempting to understand the genetics of the WAS carrier state.
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HYPOTHESIS AND EXPERIMENTAL PROTOCOL

Although genetic markers have been widely used to study a number
of X-linked diseases, to our knowledge no one has attempted to apply
these techniques to the study of X-linked immunologic disorders.

WAS

is one such immunologic disorder in which the pathophysiological concepts
remain unclear despite intensive immunological study.
at least different approach to this disorder is warranted.

Perhaps a new or
As we have out¬

lined in detail in the previous sections, there are many questions which
might be answered by a study of the expression of the WAS gene in cell
lines of the carriers.

Some of these questions are outlined below and many

are, of necessity, interrelated.
1.

Does selection take place against the WAS cells in the carrier
mothers, and if so, in which cell lines?

2.

Why do WAS carriers appear not to express an intermediate form
of the disorder?

3.

How can the platelet size information of Murphy et al^2) be
reconciled with the Lyon Hypothesis of mosaicism in the mothers ?

4.

How can the platelet physiology defects reported by Baldini^'5 6 7^,
Kuramoto et al^S), and Shapiro et_ al/^4) be reconciled with the
Lyon Hypothesis?

5.

Can the putative defective cell line(s) responsible for the disorder
in affected males be determined by studying the carrier mothers?

6.

Can a method for detecting the carrier state be found?

The solutions to the latter five questions hinge, to a great extent, on the
answer to the first question: does selection take place, and if so, where?
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This is the question we tried to answer from the outset.

Once we knew the

answer to this we could reevaluate the remaining questions and formulate
new hypotheses.
Our approach to this first question, although simple in concept,
proved to be slightly more difficult that we had planned; an occurrence
not unusual in the pursuit of science.

Briefly, we planned to locate one

or more women doubly heterozygous for G6PD and WAS.

Since the express¬

ion of the defect in the affected males appears to be limited to the bone
marrow and its hematogenous progeny we felt we should begin our study
with these elements.

We then took whole blood from the carriers and

separated it into its separate components:

platelets, erythrocytes, granulo¬

cytes, monocyte/macrophages , T-lymphocytes , and B-lymphocytes .

We

then analyzed each cell group for G6PD phenotype to see if any cell group
expressed a hemizygous phenotype rather than the heterozygous pattern
e

seen in all of several normal controls.
clusions are detailed below.

Our methods, results, and con¬
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MATERIALS AND METHODS

I.

Location of families

In order to initiate our study of WAS carriers

using linked genetic markers we first had to find an obligate or probable
WAS carrier who was also heterozygous for G6PD.

One individual who met

these requirements was located through review of the literature^) but she
was residing in Lebanon and not immediately available for study.

The re¬

mainder of our search was confined to black women since this is the only
group in which polymorphous G6PD occurs with any frequency (see Table 2).
All black WAS carriers were located with the help of the Immunodeficiency
Tumor Registry at the University of Minnesota

Registry of a family

with this group was accepted as prima facie evidence of the correct diag¬
nosis of WAS in that family.
Eight living women from five families, who had given birth to one
or more boys with WAS were contacted either personally or through their
primary physician by myself and Ms. Beatrice Spector at the Tumor Regis¬
try.

The purpose of our study was explained to them and all patients

agreed to participate.

II.

Screening for G6PD heterozygosity

Venous blood samples from each

WAS carrier were drawn into EDTA-anticoagulated Vacutainer tubes by the
women's primary physicians and reached us by first-class mail within
three or four days.

A total and differential leucocyte count was made on

each sample for future reference.

Samples were then pelleted at 450 x g
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for ten minutes at 4°C and then washed x3 with phosphate buffered saline
(PBS) pH 7.4 under the same conditions.

A 50 p.1 aliquot of washed, packed

RBCs was then drawn from the middle of the pellet and mixed with an equal
amount of lysis buffer (see under "Preparation of Reagents").

This mixture

was then frozen and thawed x3 in a dry ice-acetone bath and electrophoresed
on cellulose acetate media as described by Ellis and Alperin^7^.

G6PD-

specific enzyme staining was done according to the method of Sparkes
et al(71) and the proportion of isoenzyme bands estimated visually (^) (see
also "G6PD Electrophoresis").
If electrophoresis of RBCs showed only G6PD-B, then the buffy coat
was removed from the original RBC pellet, washed, and electrophoresed
as described for the RBCs.

This procedure allowed us to detect any women

who might be GdA“/GdB heterozygotes since the A” isoenzyme often loses
considerable activity in the RBC but retains >90% activity in the leuco(?

cytes^-O.

At our request, one patient and her two WAS sons were screened

for G6PD type by Drs. John N. Whisnant and H. N. Kirkman at the Univer¬
sity of North Carolina at Chapel Hill using similar techniques.
At the beginning of our project we considered using skin fibroblast
cultures for obtaining G6PD genotype information since these cells are not
of hematogenous origin.

Our concern was that, according to our hypothesis,

selection against the hematogenous cells carrying the WAS trait in the
carrier might possibly have taken place in the erythroid line.

If this had

indeed happened, then analysis of only hematogenous cells would have
given us woefully inaccurate information about the G6PD genotype of true
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However, both the RBCs and buffy coat from the

first patient screened expressed both isoenzyme types, implying that
selection, if it had taken place, had not affected the RBCs.

Because of

this information and the difficulty that most primary physicians might
be expected to encounter in attempting a sterile skin biopsy, it was felt
that venous blood would serve adequately for screening purposes.

III.

WAS carrier heterozygous for polymorphous G6PD

As a result of our

initial screening efforts only one definite G6PD-heterozygous WAS carrier
was found.

Patient IV is the 33 year old mother of two children, both boys

having the full-blown manifestations of WAS.

The eldest son was born in

1969 and has been plagued since birth with thrombocytopenia, chronic
otitis media, and oral herpes simplex infections.
lung problems from repeated pulmonary infections.

He has developed chronic
He has also developed

a B-cell lymphoma of the bowel and a granulomatous lung mass containing
lymphomatous foci, both of which have been surgically resected.

The

younger son was born in 1974 and has had many of the same problems includ¬
ing thrombocytopenia with hemorrhagic episodes, chronic otitis media,
recurrent pneumonias, and severe herpes simplex infections of the face.
The mother is normal in every respect.

She has no history of recurrent in¬

fections, easy bruisability, bleeding problems, or eczema.
of her medical history is unremarkable.
has no other children.

The remainder

Aside from her two WAS sons, she

There appears to be no family history of infant death

or illness similar to WAS, although information on the family of this woman
remains very incomplete at this time.

Other than our study of G6PD pheno-
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types, no other studies have been done on this woman by ourselves or others.

IV.

Preparation of reagents

Washing medium: HBSS +
Hank's Balanced Salt Solution (Flow Laboratories) containing 100 U/ml
of potassium penicillin G and 100 jig/ml of streptomycin sulfate
(Microbiological Associates).
Lymphocyte medium: RPMI-20%
RPMI-1640 culture medium (Gibco) containing 20% absorbed heatinactivated fetal calf serum, 100 U/ml of potassium penicillin G,
100 |xg/ml of streptomycin sulfate, and 2 mM 1-glutamine (Micro¬
biological Associates).
Absorbed heat-inactivated fetal calf serum:
Fetal calf serum (FCS, Gibco) is heat-inactivated for 30 min in a
56°C water bath. One volume of washed, packed sheep red blood
cells (SRBC) is then mixed with four volumes of FCS and incubated
for two hours at 4°C. The cell suspension is then spun at 800 x g
for 10 minutes to remove the SRBC. The serum supernate is then
sterilized by ultrafiltration through a 0.22|xm Nalgene filter unit.
AET-treated SRBC:
One volume of washed, packed SRBC is added to four volumes of
freshly made 0.143 M 2-aminoethylisothiouronium bromide (AET)
in distilled water, pH 8.0, and incubated for 15-20 minutes at 37°C.
SRBC are then washed x3 in PBS, and then diluted to a concentration
of 2% (v/v) with RPMI-20%.
Ficoll-Hypaque solution:
Distilled water is added to 31.77 gm Ficoll-400 (Pharmacia) to make
400 ml of solution. This solution is then mixed with 100 ml of 50%
Hypaque solution (Winthrop Laboratories), sterilized by passage
through a 0.22 [xm Nalgene filter, and stored in the dark at 4°C.
Density of the solution is 1.078 g/ml.
Dextran solution:
Dextran (clinical grade, MW 100,000-200,000; ICN Pharmaceuticals)
is dissolved in 0.9% NaCl to make a 6% solution.
Phosphate buffered saline (PBS):
3.36 ml of Solution A and 16.00 ml of Solution B is diluted to 1000 ml
with 0.9% sterile saline solution to make PBS, pH 7.4. Solution A is
made with 34.02 g KH2PO4 diluted to 500 ml with distilled water.
Solution B is made with 87.09 g K2HPO4 diluted to 1000 ml with dis¬
tilled water.

49

-

-

Electrophoresis buffer:
0.37 M Tris, 0.004 M disodium-EDTA, and 0.015 M boric acid,
pH 9.1. This buffer is made fresh either weekly or after every ten
electrophoresis runs, whichever comes first.
Lysis buffer:
Identical to Electrophoresis buffer but in addition, contains 50 \xg/ml
of nicotinamide adenine dinucleotide phosphate (NADP) (Sigma).
Staining solution:
Ten ml of staining solution containing 2 mg of MTT-tetrazolium,
4 mg of NADP, 10 mg of glucose-6-phosphate, 0.6 ml of a 1 mg/ml
phenazine methosulfate solution (prepared fresh), and 9.4 ml of 0.1 M
Tris-HCl buffer, pH 8.0 in distilled water is mixed and used immed¬
iately. All reagents are from Sigma.

V.

Preparation of cell fractions

For initial studies, 100-150 ml of venous

blood was drawn slowly through a 19 ga butterfly needle into a plastic
syringe containing 20-40 U of preservative-free heparin per ml of whole
blood, and immediately mixed.

Seven ml of venous blood was drawn into

EDTA-anticoagulated lavender top Vacutainers for platelet and cell-count
studies.

By the end of our study complete fractionations with good yield

could be carried out on as little as 30 ml of whole blood.

Blood samples

from the WAS carrier and a normal G6PD heterozygote were coded, packed
on ice, and arrived at our laboratory by air freight within 24 hours.

Blood

samples from normal G6PD heterozygote controls acquired at our laboratory
were treated identically except for refrigeration at 4°C for 24 hours in lieu
of the air freight exposure.
Whole blood from the WAS carrier was always processed with a sam¬
ple from a normal control.

The two samples were coded by someone not

involved with our project, and then the unknown samples simultaneously
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fractionated and electrophoresed as described below.

All centrigugations

were done in an IEC-PR6000 refrigerated centrifuge at 4°C.

Unless other¬

wise indicated, all cell washes were done at 450 x g for ten minutes.
Cells were counted with a Coulter Counter model no. 3037 Zp and frequently
confirmed with manual counts in a hemacytometer counting chamber.
Purity of cell fractions was determined with several methods.

Red

blood cells (RBC), polymorphonuclear cells (PMN), and mononuclear cell
(MN) preparations were Wright-Geimsa stained and subjected to 400 cell
differential counts.
inating cells.

Platelets were examined under wet mount for contam¬

Monocyte/macrophages (M/M) were observed in a hemacyto¬

meter and examined for ingestion of carbonyl iron.

T-lymphocytes and

non-T-lymphocytes were examined for the formation of E-rosettes (a T-cell
function) with AET-treated SRBC as described below.
Va.

Platelets

Platelets were prepared from EDTA-anticoagulated blood

by the modified technique of Shapiro et al^4). whole blood was first spun
at 100 x g for ten minutes to pellet the cells.

The top two-thirds of the

platelet-rich plasma was then carefully removed and spun at 1000 x g for
20 minutes to pellet the platelets, which were then washed x3 in PBS under
the same conditions.
Vb.

Erythrocytes

The remaining cell populations were purified from the

heparinized whole blood samples.

Two volumes of this anticoagulated

blood was mixed with one volume of 6% dextran solution and the RBCs
allowed to sediment at 37°C for 40 minutes^
was then removed and saved for the next step.

.

The leucocyte-rich plasma
A small aliquot of RBCs
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was then removed from the middle of the sedimented cell column and washed
x5 in PBS.
Vc.

Granulocytes

The leucocyte-rich plasma from the previous step

was then spun at 450 x g for ten minutes to pellet the leucocytes, which
were then washed x3 in PBS to remove the dextran and then resuspended in
PBS to a concentration of 5 x 10® cells per ml.

Four ml aliquots of this

suspension were then carefully layered onto three ml of Ficoll-Hypaque (FH)
solution in 15 ml conical plastic centrifuge tubes (Falcon) and spun at
400 x g for 45 minutes at 4°C

according to the method of Boyum^

.

This

technique allows separation of granulocytes (PMNs) from mononuclear cells
(MNs) by taking advantage of the different densities of these cell groups.
After centrifugation the MNs at the interface of the FH and PBS solutions
were carefully removed with a sterile pasteur pipet and saved for the next
step.

The pellet, containing PMNs and a few contaminating RBCs, was

washed x2 in PBS to remove the FH solution and was then resuspended in
0.84 % NH4CI for ten minutes at room temperature to lyse the RBCs.

The

remaining PMNs were then washed x5 in PBS.
Vd.

Monocyte/macrophages

The MN cells from the previous FH inter¬

face were washed x3 in HBSS+ to remove the FH solution and then resus¬
pended in RPMI-20% to a concentration of 4 x 10® cells per ml.

This initial

MN cell suspension contains a mixture of about 80-90% lymphocytes, 1020% monocyte/macrophages (M/M), and occasionally rare PMNs which, if
present, amount to <0.5% of the total cell population.

Two volumes of

this cell suspension was then mixed with one volume of carbonyl iron sus-
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pension (Lymphocyte Separator Reagent, Technicon Instruments Corp.) and
incubated at 37C>C on a rotator for 45 minutesAfter this incubation,
during which the phagocytic M/Ms and rare PMNs have ingested the iron
particles, six ml aliquots of the cell/iron suspension were then layered over
FH gradients and spun at 400 x g for 20 minutes.

The lymphocytes, which

are unable to phagocytize the iron particles, remained at the interface
and were carefully removed with a sterile pipet and saved.

The monocyte/

macrophages in the pellet were then carefully washed x2 in HBSS+.
Ve.

T-lymphocytes

The monocyte-depleted lymphocytes from the pre¬

vious FH interface were washed x3 with HBSS+ and resuspended to a concentration of 6 x 10

cells per ml in RPMI-20%.

T-lymphocytes were then

rosetted with AET-treated Sheep RBCs as described by Kaplan et al^7^.
Three ml of lymphocyte suspension, three ml of absorbed FCS, and six ml
of 2% AET-SRBC were gently mixed in a 50 ml conical polypropylene centri¬
fuge tube (Falcon) and then incubated for ten minutes in a 37°C water bath.
This suspension was then spun at 200 x g for five minutes at room temper¬
ature (RT) to pellet the cells and bring the lymphocytes and AET-SRBCs into
closer proximity.

The tubes were then incubated for ten minutes at RT,

mixed gently, again spun at 200 x g for five minutes, and then reincubated
for 45 minutes at RT.

The supernate was discarded, replaced with RPMI-20%,

and the pellet gently resuspended.

A small aliquot was mixed with a via¬

bility exclusion dye (eosin Y) and the percent rosetted viable lymphocytes
determined.

If rosetting was adequate, five ml aliquots of this cell sus¬

pension were layered onto FH gradients and spun at 900 x g for 20 minutes
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al/^).

This separation takes advantage

that only T-lymphocytes will form rosettes with AET-treated

SRBCs, and the fact that rosetted lymphocytes have a higher density than
non-rosetted lymphocytes and will thus pass through the FH gradient.
The non-rosetted mononuclear cells at the interface were removed
and saved.

The cells in the pellet were carefully resuspended and exam¬

ined for rosetting.

If the percent E-rosettes in the pellet was lower than

90-95%, the cell suspension was run over a second FH gradient.

The

pellets containing >90-95% E-rosetting cells were then resuspended in
0.84% NH4CL and incubated for ten minutes at RT to lyse the SRBC.

The

resulting T-lymphocyte suspension was then pelleted and washed x3 in
HBSS+.
Vf.

Non-T lymphocytes

The non-rosetting mononuclear cells from the

interfaces in the preceding step were retreated with AET-SRBCs if cell
numbers were sufficient, and rerun over FH gradients.

The cells remaining

at the interface were then washed x3 in HBSS+.
After monocyte depletion with carbonyl iron, the mononuclear cell
pool consists essentially of lymphocytes.

The lymphocytes removed by

E-rosetting are essentially pure T-lymphocytes as the ability to form
rosettes with AET-SRBCs is a function found exclusively in that cell line.
The remaining non-rosetting lymphocyte pool actually consists of a mix¬
ture of B-lymphocytes, null cells (non-B non-T lymphocytes), T-lympho¬
cytes that failed to rosette for some reason, and a very few contaminating
monocytes and PMNs that have found their way into this group despite all
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the intervening steps designed to eliminate them.
these cells are B-lymphocytes.

The vast majority of

However, since we did not assay this

pool for specific B-lymphocyte markers, we prefer to label this pool as
non-T (non-rosetting) lymphocytes.

VI.

Electrophoresis

All fractionated cell samples were pelleted and

resuspended in a small amount of lysis buffer and frozen and thawed x3
in a dry ice-acetone bath.

Small aliquots (1-2 jjl1) of each sample were

then applied with a fine-point artist's brush to mylar-backed cellulose
acetate plates (Sepraphore-X, Gelman Instrument Co.) previously soaked
in ice-cold lysis buffer for 30 minutes.

The plates were then immediately

electrophoresed at 300 V for 40 minutes at 4°C in a Gelman Deluxe Electro¬
phoresis Chamber filled with Tris-EDTA-Borate buffer, pH 9.1, according
to the method of Ellis and Alperin^^.

Some of the initial screening sam¬

ples were electrophoresed on cellulose acetate strips (Sepraphore-III, Gel¬
man) under identical conditions except at 400

for one hour.

After electrophoresis, the separated G6PD isoenzyme bands were
made visible by the enzyme-specific staining method of Sparkes et al^^.
Ten ml of stain solution was mixed as described under "Preparation of
reagents" and used immediately.

Cellulose acetate plates were removed

from the electrophoresis unit and immediately immersed in the stain solution
for 15 seconds, briefly allowed to drain on a filter paper, and then placed
acetate-side down on a glass plate.

Excess stain solution was pressed

out, the edges sealed with masking tape to prevent drying, and the enzyme
bands allowed to develop in the dark for 15 minutes at RT ^70^.

Cellulose
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acetate strips were stained with the filter paper method of Sparkes et al^-U.
As mentioned previously, the staining procedure is enzyme-specific.
Only human G6PD isoenzymes will precipitate the dye; sheep G6PD (from
SRBCs) will not be stained by this procedure.
works as follows.

Briefly, the staining reaction

Through the compounds in the staining solution, G6PD

reduces NADP to NADPH, which in turn reduces the yellow water-soluble
MTT-tetrazolium dye to a purple water-insoluble formazan dye.

Purple

bands are thus formed where the G6PD isoenzymes are present on the plate.
Hemoglobin often causes non-specific precipitation of formazan dye as
well, but this does not interfere with the detection of G6PD because the
hemoglobin migrates much slower than the G6PD isoenzymes.

Figure 3

illustrates the separation of hemoglobin and these isoenzymes as detected
by spectrophotometric scanning, which will be discussed below.
After the plates or strips were developed, they were immediately
immersed in a 1% formaldehyde solution for 10-20 minutes to denature the
hemoglobin band present in the RBC samples, stop the other enzymatic
reactions, and to help preserve the plates.

If the hemoglobin was not de¬

natured it would often migrate into the area of the two G6PD isoenzyme
bands as the support medium dried.
Two methods were used in an attempt to estimate the isoenzyme ratios
in each sample.

The first method involved clearing the translucent support

media in mineral oil or other solutions to render them transparent for optical
scanning. Before scanning could be done, however, the absorption peak of
the formazan dye had to be determined.

A small amount of precipitated dye
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FIGURE 3.
Spectrophotometric scan of a representative G6PD isoenzyme
electrophoresis.
A hemolysate from a normal heterozygous control was prepared, electrophoresed, and stained as described in the text. The cellulose acetate
strip was cleared with mineral oil and scanned at 575 nm in a Beckman
DU-2 spectrophotometer with slide scanner.
Note that the G6PD isoenzymes migrate faster than hemoglobin A and that
G6PD-A migrates faster than G6PD-B, the distance between the two peaks
being about four millimeters. Note also the high background. The origin
is not shown on this graph as it was cut away when preparing the cellulose
acetate strips for scanning. The abcissa shows relative distance only,
not distance from the origin.
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was dissolved in methanol, placed in a scanning spectrophotometer, and
its absorption spectrum between 350 nm and 750 nm determined (see figure
4).

The wavelength of maximum absorption, 57 5 nm, was then determined

from this curve.

Once the electrophoresis medium had been cleared it was

placed between two glass slides and scanned at 575 nm in a Beckman DU-2
spectrometer with Gifford slide transport.
G6PD electrophoresis is shown in figure 3.

An optical scan of a typical
The areas under each peak

were determined with an electronic integrator and the G6PD isoenzyme
ratios in each sample calculated from these numbers.
Two major problems with this technique of scanning
estimating became rapidly apparent.

and G6PD ratio

The first was that clearing of the

support medium, though necessary for optical scanning, drastically reduced
the intensity of the stained bands.

The second problem was that the

optical scanner was at the extreme limit of its sensitivity.

With these

two problems combined, we found that bands were occasionally not visual¬
ized at all, the background "noise" was quite high, and the two G6PD
isoenzyme bands often could not be discriminated as two bands by the
machine even though two bands were readily distinguishable by the human
eye.

For these reasons the mechanical scanning technique was abandoned.
The second method we adopted proved much more reliable.

Since the

human eye appeared to discriminate two G6PD bands much better than the
spectrophotometer we decided to abandon machines altogether.

Electro¬

phoresis plates were removed from the formaldehyde solution and, when
thoroughly dried, immediately examined on a light-diffuser table.

The
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FIGURE 4.

Absorbance spectrum of purple formazan dye in methanol.

Yellow MTT-tetrazolium was reduced to the insoluble purple formazan
dye which was then pelleted and dissolved in methanol for determination
of its absorbance spectrum by scanning spectrophotometry. The visible
light wavelengths between 350 nm and 750 nm were scanned. The arrow
indicates the 575 nm wavelength used to scan the G6PD electrophoresis
strips.
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A:B isoenzyme ratio in each sample was then estimated by comparison
with known standards.

This method allowed us to detect the presence of

an isoenzyme fraction making up as little as 5% of the total sample.

Photo¬

graphs of each plate were taken as well, although the sharpness of the
bands was much more apparent to the eye than to the camera.

After esti¬

mation of the G6PD isoenzyme ratios the plates were stored in a notebook
in the dark.

<?
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RESULTS

I.

Screening Program

The outcome of our screening program to locate

a G6PD-heterozygous WAS carrier is shown in Table 3.

One probable and

seven obligate carriers from five different families were tested for G6PD
phenotype.

As a result of examination of their RBCs, only one definite

G6PD heterozygote was found.
buffy coat showed 15% G6PD-A.

On electrophoresis, both her RBCs and
This woman, patient IV, was the only

WAS carrier on whom the cell fractionation studies were done.

Isoenzyme

results on blood samples from her two sons unfortunately were not helpful
in determining which G6PD isoenzyme type was linked with the WAS allele.
One WAS son was G6PD-A and the other affected boy was G6PD-B, implying
a crossover in one of the children.
Three of the women screened appeared to be phenotypically G6PD
type B and the remaining four were type A.

This latter frequency was much

higher than one would expect, considering an AA genotype frequency of
0.09 in black American women (see Table 2).

It is most easily accounted

for by our very small sample size and the fact that three of the four women
were sisters.
Of further interest was the observation that patient V-3a showed
only B enzyme in her RBCs and buffy coat despite the fact that her mother,
patient V-3, showed only the A isoenzyme.

If the mother's genotype was

AA, then it is genetically impossible for her daughter's genotype to be BB.
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TABLE 3.

Results of G6PD isoenzyme phenotype screening in eight
black carriers of Wiskott-Aldrich syndrome.

G6PD isoenzyme type in:
patient #
I
II
III
IV
*V-1
V-2
V-3
V-3a

erythrocytes

buffy coat

B
A
B
AB
A
A
A
B

WAS son(s)

B
—

--

B
AB

—

one A, one B

—

—

-A
B

-—

(--) = not tested
*

Patients V-l through V-3a are all from the same family. V-l, V-2, and
V-3 are sisters; V-3a is the daughter of V-3. Note the discrepancy in
their G6PD phenotypes, a genetic impossibility. Possible reasons for
this are discussed in the text.
Patient IV was the only definite G6PD heterozygote detected and thus
was the only patient studied in detail. Of interest is the fact that one
of her two affected sons is G6PD-A and the other G6PD-B, implying
a crossover. We were thus unable to locate the WAS gene to a specific
X-chromosome. See text for further information.
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One of these two women must therefore be a heterozygote.

There are several

possibilities that could explain our apparent inability to detect this.

The

first is that the heterozygote might be one of the few women who express
a large majority of one isoenzyme type.

If this type were to make up >95%

of the total, the woman would appear to be homozygous because of the 5%
sensitivity threshold of our G6PD assay.

Another possibility could be that

the mother is really genotype A “A and her daughter A~B.

The mother would

show only A on electrophoresis and it might be possible to miss a faint A"
band in the daughter.

However, the daughter's buffy coat showed only a B

band, and it should be remembered that the A” enzyme retains >90% of nor¬
mal activity in nucleated cells.

In addition, the mother's RBCs showed

a normal G6PD staining density after electrophoresis, a crude measurement
of enzyme activity implying that she does not have substantial A” enzyme.
A third possibility is that the daughter could be heterozygous for G6PD in
normal tissue such as skin fibroblasts, but hemizygous in her RBCs and
leucocytes as a result of a selection process that we have hypothesized.
However, we chose not to examine skin fibroblasts since the first patient
screened (patient IV) had heterozygous RBCs.

This of course does not rule

out selection in the RBCs of patient V-3a but no selection in the RBCs of
patient IV.

These possibilities will be discussed in depth later.

A fourth

possible cause of this discrepancy is the presence of a mutant form of
G6PD in one of these women, although these are quite rare.

The answers

to the puzzle that this family presents unfortunately must await further
scrutiny of non-hematogenous tissues in these women, as well as a de-
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tailed analysis of the G6PD pedigree in the entire family,

II.

Cell Fractionation

Samples of whole blood from four normal con¬

trols and two separate preparations from our WAS carrier were fractionated
into RBCs, platelets, granulocytes, monocyte/macrophages, T-lymphocytes,
and non-T lymphocytes.
Table 4.

The purity of each cell fraction is summarized in

Purity of RBCs and platelets was virtually 100%, with less than

one contaminating cell per 10,000 RBCs or platelets.

The platelet samples

from control 4 and our second carrier preparation, pt. IV(#2), rather than
being prepared from 24 hour old blood, were isolated immediately after re¬
moval from the patient by pelleting from platelet-rich plasma as described
previously.

This unwashed pellet was then sent to us on ice with the whole

blood samples.

The platelet-rich plasma prepared from pt. IV (#2) was re¬

ported to have shown slight hemolysis.

Some of this was carried over in

the unwashed platelet pellet for when the platelets were prepared for elec¬
trophoresis , a very slight trace of hemoglobin was noted.

However, the

presence of this hemolysis (and possible contaminating G6PD isoenzymes)
did not affect the results of isoenzyme ratio determination, as shown below.
The purity of granulocyte (PMN) preparations from control samples
drawn in our lab was routinely >93%, the contaminating cells being mostly
mononuclear cells with a few RBCs that would not lyse with ammonium chlor¬
ide,

The poor granulocyte purity in control 4 and the two WAS carrier prep¬

arations was due to the quality of blood samples shipped by air freight.
Although adequately heparinized and handled impeccably, a fine fibrin clot-
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Purity of representative cell fractions separated from whole blood of controls and
one WAS carrier.

cn
r-H
.-

Q)
C
O

X

X!

O
O

4-1

O

C

X
<U
Sh

II
cn

O
DQ
cc
X

CU

j_»

c
o

CU
rC

4-1

CO

c

(0

X
cu
X!
—H
Sh
o
cn
CU
X

c

&

cu
s-.

0)

jC
Sh

3
m
u.

O
X
a;

j_j

cu

a)

cn

c
CU

cn
CU
s-.

a

cn
CO

£
cn
cn
r-H

O
S

<u

rfi

TABLE 4.

1
o
cu

4—1

Jl

Cn

i

.

C/D

cn
(0
>,
j_i
'rH
Sh
3
CD.
Sh
O
M—t

•
cn
cu

j->
>,

o
o
j:
a
£
e
r—i

X 1
cu H
>,
fO II
cn cn
cn
fO rH
<U
X O
C 1
3 Eh
«
X
CU cn
Sh cu
CO j-i
a >i
cu o
Sh o
CD. r—H
3
CU C
Sh
CO
CU Sh
£ Cn
cn
<u

II
cn
a
£
£
CO 2
CO CL

65-

-

like material was present in all three samples on arrival in our laboratory.
Although the etiology of this problem remains unknown, we feel that its
presence in both control and WAS carrier samples indicates that it is most
likely a result of technique rather than a defect intrinsic to the WAS carrier.
This clot-like material was not observed in samples from controls 1-3, which
were drawn in our lab but treated identically.

These control samples sedi¬

mented normally with dextran, and cell fractionation was accomplished with¬
out problems.

The presence of the clot-like material in the samples from

control 4 and our WAS carrier, however, made dextran sedimentation impos¬
sible and granulocytes had to be prepared from the buffy coat;

a procedure

which gave poorer yield and more RBC contamination than the dextran sedi¬
mentation method.

This clot also caused the leucocytes to clump and thus

separate poorly through the FH gradients.

As a result, granulocyte and

mononuclear cell fractions had to be passed over several FH gradients to
obtain usable purity, even though this greatly diminished the yield.

Despite

these efforts, granulocyte samples from these patients remained heavily
contaminated with mononuclear cells.
In contrast, however, mononuclear cell fraction purity was quite high,
usually >92%.

Contaminating cells were usually granulocytes and RBCs

since ammonium chloride lysis had not yet been done.

The granulocytes

present in this fraction were a potential problem, since the next step in
purification was monocyte/macrophage isolation by carbonyl iron ingestion.
Granulocytes are able to phagocytize iron particles as well as the monocytes,
and these cells are thus separated together by our technique.

Purity of the
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monocyte/macrophage pool was judged by the presence or absence of iron
particles in viable cells rather than by monocyte-specific histochemical
staining.

It is therefore possible that the monocyte/macrophage pool con¬

tained undetected granulocytes, although the total mononuclear cell pool
was substantially granulocyte-free prior to the carbonyl iron isolation.
As can be
excellent.

seen in Table 4, the purity of lymphocyte fractions was

T-lymphocytes were >92% pure by E-rosette formation whereas

the non-T lymphocytes were substantially rosette-free.
this latter cell pool were mostly B-lymphocytes.

The cells comprising

Other mononuclear cells

potentially present in this preparation include null cells (non-B non-T lympho¬
cytes), T-lymphocytes that did not rosette, and monocytes that did not in¬
gest iron.

Since B-lymphocyte-specific immunofluorescent staining was

not done on these samples however, the exact percentage of B-lymphocytes
found in them is unknown.

We have therefore chosen to classify this group

as non-T lymphocytes.
Results of the G6PD phenotype determination on lysates of the
various cell fractions from controls and our WAS carrier are summarized
in Table 5.

The ratio of G6PD isoenzymes in all the normal controls

was remarkably constant from cell line to cell line within the same indi¬
vidual.

In addition, RBCs, granulocytes, monocytes, and non-T lympho¬

cytes from the WAS carrier showed similar G6PD ratios.

In contrast to

the pattern seen in normal controls however, the platelets and T-lympho¬
cytes from our WAS carrier showed a complete absence of the A enzyme
on multiple electrophoreses.

This absence of the A enzyme in these
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nificance of this absence is explained in the text.

G6PD isoenzyme ratios in different cell fractions isolated from whole blood of three
normal heterozygous controls and one doubly heterozygous WAS carrier.
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samples was felt to be the result of a process within the patient rather
than a result of our technique, since the pattern was seen in two dif¬
ferent cell separations done several months apart.

Furthermore,

the A

band in control samples was always visualized when these samples were
electrophoresed simultaneously with the platelet and T-cell fractions
from our WAS carrier.
Despite the 56% contamination by lymphocytes in one granulocyte
sample and the 41% contamination in the second sample from the carrier,
it was felt that the 15:85 isoenzyme ratio in her granulocytes was re¬
liable for two reasons.

The first was that A:B ratios in the buffy coat

preparations from the WAS carrier matched the 15:85 ratio seen in her
RBCs.

If her granulocytes had been missing the A enzyme, this, com¬

bined with the complete absence of the A enzyme seen in her T-lymphocytes, would have resulted in a buffy coat ratio much lower than the
15:85 actually seen.

The second reason involves similar calculations

since our contaminated granulocyte preparations resemble a buffy coat
in many ways.

If pure granulocytes were actually missing the A enzyme,

but were 50% contaminated with cells expressing 15% A (the largest
amount of A enzyme any of her cells can express), then we should see
an electrophoresis pattern containing only 7.5% A enzyme.

In addition,

if half of the contaminating cells were T-lymphocytes (a reasonable
estimate) we would expect to see a granulocyte pattern showing less
than 5% A enzyme.

Despite similar amounts of contamination however,

the actual granulocyte preparations from our carrier still showed 15% A.
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Since this is the pattern found in her RBCs and other heterozygous
cell lines of higher purity than the granulocytes, we can only con¬
clude that the granulocytes of our carrier were heterozygous as well,
despite contamination.
The purity of the remaining cell fractions was sufficiently high
such that their electrophoresis patterns were felt to be an accurate
reflection of their G6PD phenotype.

To summarize our results, cell

fractions from normal controls showed remarkably constant G6PD iso¬
enzyme ratios from cell line to cell line.

In contrast, cell fractions

from a WAS carrier showed constant isoenzyme ratios in RBCs, granulo¬
cytes, monocyte-macrophages, and non-T lymphocytes;

but complete

absence of the A enzyme in platelet and T-lymphocyte pools.

The

possible causes of this pattern and its significance will be discussed
below.
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DISCUSSION

As mentioned previously, the apparent discrepancy between the
G6PD genotype of our WAS carrier and the G6PD phenotype of her plate¬
lets and T-lymphocytes is not methodological.

Our results are most

unusual since similar hemizygous G6PD phenotypes have been seen
only in monoclonal tumor cell lines(62,63) ancj in carriers Qf the Xlinked disorders of HPRT deficiencyand abnormal phosphoribosylpyrophosphate synthetase (PRPPS) activity(^8).

Our WAS carrier was

not ill and is presumed not to be a carrier for the latter two disorders
since their occurrence is quite rare and there was no evidence that
her two sons express those disorders in addition to WAS.

Furthermore,

RBCs from carriers of these latter two disorders show hemizygous G6PD
expression, whereas the RBCs from our WAS carrier were heterozygous.
Several mechanisms for this apparent hemizygous expression in
our WAS mother are possible.
If,

Let us first consider her platelets only.

as mentioned earlier, the megakaryocytes from a WAS carrier were

a mosaic population with 50% making "defective" platelets and 50%
making normal platelets, one might still expect only 10% of the total
peripheral platelet pool to have originated from WAS megakaryocytes
because of production and destruction dynamics.

Thus even though

most of her cell lines would have a G6PD isoenzyme ratio of 50:50,
one would see a ratio of 10:90 in her platelet pool.

However, our
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WAS carrier appears to be a 15:85 mosaic rather than 50:50.

If the

former ratio was also seen in her megakaryocytes, with 15% producing
abnormal platelets and 85% producing normal platelets, then by extra¬
polation one might expect <4% abnormal platelets in the peripheral
platelet pool.

This pool would then have a G6PD ratio of less than

4:96 but we would be unable to tell the difference between this and
a ratio of 0:100 since

the sensitivity threshold of our G6PD assay

for one isoenzyme component in a heterozygote is 5%.

The hemi-

zygous result found in the platelet pool of our WAS carrier might there¬
fore be a result of platelet dynamics combined with her uneven Lyonization.
This model however, cannot explain the hemizygous findings in
T-lymphocytes so we must therefore consider additional ideas.

The

hemizygous G6PD expression in both T-lymphocytes and platelets in our
WAS carrier are most likely the result of a genetic event involving
bone marrow stem cells or their hematogenous progeny.

A number of

genetic mechanisms could be responsible for these findings, including
recombination, somatic mutation, or deletion.

However, in the case

of the X-chromosome it seems most likely that the mechanism involves
X-inactivation.

It appears, at least in the T-lymphocytes and possibly

the platelets or megakaryocytes of the WAS carrier, that either X-chromo¬
some inactivation is not random, or that following random inactivation
there is competition and selection against one of the two cell lines.
The most appealing and intriguing theory is that selection takes place
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against the megakaryocytes and T-lymphocytes expressing the WAS
allele because of some intrinsic defect in those cells.

Unfortunately

we cannot tell whether the hemizygous cell lines carry the normal
allele or the WAS allele since one WAS son expresses G6PD-A and
the other WAS son expresses G6PD-B, implying a crossover in one of
the children.

Despite this missing bit of evidence, we still feel that

selection against cells bearing the WAS allele has taken place in the
hemizygous cell lines of our WAS carrier.
The theory of selection in our WAS carrier is supported by studies
in several other X-linked disorders in which selection appears to have
taken place against cell lines bearing the defective allele.

For exam¬

ple, Nyhan et. al^) were intrigued by the observation that, in the
carriers of Lesch-Nyhan disease (HPRT deficiency), fibroblast cultures
showed HPRT activity intermediate between normals and affected boys
(as expected), but RBCs and lymphocytes from carriers appeared to show
full normal activity.

To investigate this discrepancy they found a wo¬

man doubly heterozygous for both HPRT deficiency and polymorphous
G6PD.

They found, as had others, that fibroblast cultures from this

woman were made up of two clones, one showing full HPRT activity
and expressing G6PD-B, and the other clone showing absent HPRT ac¬
tivity and expressing G6PD-A.
cyte pools showed only G6PD-B.

However, studies on her RBC and leuco¬
The complete absence of the popula¬

tion of cells expressing G6PD-A and HPRT deficiency would of course
explain why the blood cell pools had full normal activity rather than
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the intermediate activity seen in the heterozygous fibroblast cultures.
Nyhan et a], concluded that there was selection against the HPRT defic¬
ient stem cells in the bone marrow resulting in the hemizygous expres¬
sion of G6PD-B and normal HPRT in . 3Cs and leucocytes from the car¬
rier.

To our knowledge, they have not assayed each separate leuco¬

cyte population to see if all hematogenous cell lines are hemizygous
or whether this is limited to one or two specific cell lines.
A similar finding was seen by Yen £t

when studying the

X-linked inheritance patterns of phosphoribosylpyrophosphate synthetase
(PRPPS) in families with a mutant form of the enzyme.

This mutant

enzyme had a different electrophoretic mobility than the normal enzyme,
and in addition had increased enzyme activity rather than the decreased
activity usually seen in hereditary disease states.

This group found

that fibroblasts from carrier mothers showed PRPPS activity intermediate
between normals and affected males and that cultures of these fibro¬
blasts, just as in Lesch-Nyhan carriers, were comprised of two clones,
one with normal PRPPS activity and electrophoretic mobility, and the
other clone expressing the elevated activity and electrophoretic mobility
seen in affected males.

Erythrocyte and purified lymphocyte pools,

however, did not display the mixture of PRPPS enzymes seen in fibro¬
blast pools, but rather, the full elevated activity and electrophoretic
pattern of the mutant enzyme.

The presence of only the mutant enzyme

in these hematogenous pools resembled the findings in the carriers of
Lesch-Nyhan disease.

However, Yen et _al felt that competition in the
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stem cells favored selection of the
PRPPS activity.

-

mutant cells expressing increased

They also reported that another grouphad made

similar observations in a different family with increased PRPPS activity.
Selection in the carrier from this family appears to have favored the
normal enzyme.

Yen ejt al therefore concluded that the hemizygous

RBCs and lymphocytes in the carriers of mutant PRPPS activity was
more likely a result of selection rather than non-random X-inactivation
since a different isoenzyme appeared to be favored in each of the two
cases.
The results of our experiment and the supportive evidence of
these other X-linked models suggest that there is either non-random
X-inactivation in megakaryocytes and T-lymphocytes or that selection
against one of the X-chromosome clones has taken place in these cell
lines.

However, because of the particular cell lines that appear to

be hemizygous, we believe that this process is one of selection rather
than non-random inactivation.

Let us assume for the moment that

either event could occur in our WAS carrier.

This event cannot have

taken place at the level of the pluripotent stem cell since the RBC/
granulocyte, monocyte, and non-T lymphocyte pools are heterozygous.
Because T-lymphocytes are hemizygous and non-T lymphocytes are not,
it appears that inactivation or selection has taken place after
cyte precursors have migrated through the

the lympho¬

thymus, which first takes

place during the seventh or eighth week of gestation^).

However,

Migeon and Kennedy^) and Fialkow^^^ have determined that random
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X-inactivation is definitely complete by the fourth week of gestation
and probably occurs as early as the 16 cell blastula.

If our hemi-

zygous pattern was a result of non-random X-inactivation taking place
at this stage of embryonic development, then all lymphocytes should
be hemizygous since the thymus has not yet developed.

In our WAS

carrier however, only the thymus-derived lymphocytes are hemizygous,
implying that the event took place after development of the thymus.
Since the timing of this event is clearly later than the appearance of
X-inactivation, we submit that the hemizygous pattern in T-lymphocytes
and platelets can only be a result of selection against cells bearing
a particular X-chromosome.
As mentioned before, which particular X-chromosome has been sel¬
ected against is unknown.

If, however, the WAS lesion involves a

defect in or inhibitor of the Krebs cycle and subsequent defective energy
production as has been postulated by Shapiro e_t al/34), then the cells
expressing this defect in the heterozygous carrier might certainly be
at a competitive disadvantage.

We feel therefore that the cells expres¬

sing the WAS allele are the most likely to be the ones missing from
the T-lymphocyte and platelet pools.
The hemizygous platelet pool can be explained as resulting from
either platelet dynamics or actual selection against one of the mega¬
karyocyte pools, but the hemizygous T-lymphocytes can only be explained
by selection.

We feel it is most likely that both hemizygous groups

are a result of selection, and that this process was directed against
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However, it should be remembered that the hetero¬

zygous cell lines in this mother still carry the WAS gene.

It is cer¬

tainly reasonable to expect that selection would take place only in a
cell line expressing the WAS allele, but whether all cell lines expres¬
sing this allele have been selected against is unknown.

In other

words we don't know for sure that expression of the WAS allele in car¬
riers is limited only to the platelets
cytes.

(megakaryocytes) and T-lympho-

If this was the case however, it could certainly be one explan¬

ation as to why the carriers manifest no intermediate form of the dis¬
order seen in their affected sons.
Let us now compare our anti-WAS selection theory with the plate¬
let data in carriers.

The platelet size data of Murphy et al^2) indicate

that all platelets in the carrier are of normal size.

On page 33 of this

thesis three possible explanations were considered.

The first was that

the megakaryocytes were a mosaic (no selection) but that abnormal
platelets were destroyed so fast that their presence could not be detected
by Murphy's technique.

The platelet pool would thus appear hemizygous.

Although we have no information about the megakaryocytes themselves,
the platelets in our carrier fit this picture and this theory is still pos¬
sible .
Again assuming no selection in megakaryocytes, the second explan¬
ation for the absence of abnormally small platelets was that the normal
cells produced some positive "factor" enabling WAS megakaryocytes to
produce normal platelets.

Though of normal size, the platelets would
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be genetically heterozygous.
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Our finding of hemizygous platelets contra¬

dicts this theory.
The third explanation was that selection had taken place, leaving
only normal megakaryocytes producing a normal hemizygous platelet pool.
Our data support this theory of selection as well as the platelet dynamics
theory.

The only way to determine which is correct is to study the

clonal patterns in the megakaryocytes themselves, for in the first model
these cells will be heterozygous while in the selection model they will
be hemizygous.
Regardless of which model is correct, one can infer from our data
that the vast majority, if not all, of the platelets in the peripheral
blood of our carrier are of monoclonal origin.

Murphy's data indicate

that these platelets are of normal size and thus they have probably
originated from normal megakaryocytes.

How then can one explain the

physiological defects reported by Baldini^), Kuramoto et al^5), and
Shapiro et_ al(34)?

xhree explanations taking all of this into account

were proposed earlier.

The first was that megakaryocytes were a mosaic

(no selection) but that normal cells exerted some "positive influence"
causing them to produce normal-sized platelets and therefore a hetero¬
zygous platelet pool.

The WAS cells then exerted a "negative influence"

on all the platelets, causing the abnormal physiologic responses.

This

theory was quite awkward, but is definitely contradicted by our platelet
findings.
The second theory involved megakaryocyte selection resulting in
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a normal hemizygous platelet pool upon which a "negative influence"
(perhaps a Krebs cycle inhibitor produced by other WAS cells) results
in abnormal physiologic responses.

Our findings support the idea of

a normal platelet pool, and the existence of a soluble inhibitor is cer¬
tainly possible.

However, if selection has occurred in all cell lines

expressing the WAS allele, from where could this proposed factor origin¬
ate?
The third explanation was that the physiologic defects seen in
the platelets of carriers were an artifact and thus do not actually exist.
From our data and that of Murphy et, <al it is quite clear that the platelet
pool in these carriers is essentially of normal origin.

The proposed

abnormal platelet responses are thus very intriguing for there is much
to suggest that they should not exist, yet they do appear to be present
in some cases.

They remain a puzzle to say the least.

One of our reasons for initiating our study of the WAS carrier state
was to see if we could locate the cell line responsible for the immune
defect in the affected sons.

Almost all of the hematogenous cells have

been implicated at one time or another but no actual defect has been
found in any of them.

Is it possible to locate this defect in the sons

by studying their mothers?
to attempt this.

We must make several assumptions in order

First, we do not know if the apparent selection we

see in the carrier has occurred against the WAS allele or the normal
allele, although we suspect the former.

Assuming this, we still do not

know if there is selection against all cells expressing the WAS allele
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We also do not know whether the cells selected against

in the carrier are the same cells that are responsible for the defect in
their affected sons.

At the very least, we could assume that if a WAS

cell were defective in the mother it should be defective in the son.
Understanding full well that our assumptions are unproven, we
would like to make the intuitive leap and suggest that the hemizygous
T-lymphocytes found in the mother implicate the T-lymphocyte as at
least one if not the only cell responsible for the immune defects seen
in the affected males.

This

notion has already been supported to some
(12)

extent by the bone marrow transplantation work of Parkman et alv
discussed earlier.

'

as

The mechanism by which the T-cell could produce

these defects is unknown although it may lie in the inability of the
T-lymphocyte to recognize the immune message presented to it by any
of several methods.

The other cell line that

is

frequently suggested

as the cause of the defects in afferent immunity in this disorder are
the monocytes which play a large role in processing and presenting
antigens to the T-lymphocyte.

Because

of our results in the mother

showing that her monocyte/macrophage pool was heterozygous we feel
that the monocyte/macrophage in the boys is not responsible for the
immune defects.
In addition to the suggestions about the basis for the immune
defect in the sons, our results in the carrier mother suggest a possible
method for detecting the carrier state.

If all carriers indeed express

hemizygous platelet and T-lymphocyte pools with respect to the X-chromo-
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some then detection of the carrier state would involve assaying one of
these cell lines for the hemizygous expression of a commonly heterozy¬
gous X-linked marker.

Isolation of purified platelets is quite easy, and

isolation of T-lymphocytes is fairly uncomplicated as well.

However,

the most common X-linked marker currently known is G6PD, which is
heterozygous in only 42% of black women.

Thus roughly half of the

black women suspected as being carriers could be detected, but the
techique is useless for the majority of the population who are homo¬
zygous for this marker.

Widespread application of this hemizygous

detection technique will have to await the discovery of other more
common heterozygous markers (either structural or genetic) on the X
chromosome.
We should hasten to point out several problems.

Because of

the apparent crossover in one of our carrier's WAS sons, we were unable
to locate the WAS trait to a particular chromosome.

In addition we

have studied only one carrier and do not know whether our observations
were a freak occurrence or whether they are found in all carriers of
Wiskott Aldrich syndrome.

The clonal status of the megakaryocytes

in our carrier is also unknown.

Studies are currently underway to

locate and test more doubly heterozygous WAS carriers, however, and
we feel that evidence to support our theories will be shortly forthcoming.
The technique of using genetic markers has been widely used
in the study of tumors and hematological disorders, but to our knowledge
we are the first to apply it to the study of the immune system.

This
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preliminary study has been useful in understanding some of the aspects
of Wiskott-Aldrich syndrome and may indeed prove useful in understand¬
ing the other X-linked disorders of immunity such as X-linked immuno¬
deficiency with hyper-IgM, X-linked infantile hypogammaglobulinemia,
and the X-linked form of severe combined immunodeficiency.

One major

drawback is the extreme rarity of these diseases, and the even more
remote possibility of finding a carrier heterozygous for a studiable Xlinked marker.

Our work however, serves as a model for the application

of this technique to the understanding of immune disease and the nor¬
mal immune system.

e

SUMMARY

In an attempt to locate the cell lines responsible for the immune
defects in boys with the X-linked Wiskott-Aldrich syndrome, the Xinactivation patterns of hematogenous cell lines in the heterozygous
carriers were studied with the use of glucose-6-phosphate hehydrogenase (G6PD) as a genetic marker.

One probable and seven obligate

carriers from five black families were screened for G6PD genotype
and one heterozygote was detected.

Erythrocytes, granulocytes, mono¬

cyte/macrophages, and non-T lymphocytes showed identical G6PD
isoenzyme ratios.

However, the platelets and T-lymphocytes from

this carrier showed the complete absence of the A isoenzyme.

This

pattern was not seen in normal controls, who showed a remarkable
consistency of isoenzyme ratios in all cell lines.

We feel that the

hemizygous platelets and T-lymphocytes found in the carrier result from
selection against those cells bearing the Wiskott-Aldrich allele and
that by inference the T-lymphocyte is at least partially responsible
for the immune defects seen in the affected males.

A possible method

for detection of the carrier state, as well as the application of this
chromosome marker technique to other X-linked immunologic diseases
is discussed.
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